Keiran Smalley
@labsmalley
Director of the skin cancer research center at Moffitt. Interested in melanoma: cutaneous, acral, pediatric and uveal. #melanoma #uveal #pediatric 🇺🇦
ID: 1193910621378695168
http://labpages2.moffitt.org/smalley/ 11-11-2019 15:17:42
1,1K Tweet
1,1K Followers
1,1K Following
Join us for the Melanoma Metastasis session at the Society For Melanoma Research Congress 2024. Fantastic lineup of speakers presenting the latest discoveries in melanoma metastasis. Grand Ballroom A/B #melanoma #SMR2024
Super mega happy for Patricia Possik getting the Chris Marshall Award! Paty has done a lot for the Latin American #melanoma research and patient community. Congratulations Paty!!! Society For Melanoma Research
A new study presented at #SMR24 annual meeting could influence how early-stage melanoma patients are selected for sentinel node biopsy, a surgical procedure often used to determine if melanoma has spread to the lymph nodes. Society For Melanoma Research bit.ly/3NtUVOs
Our latest published article in Clinical Cancer Research Clinical Cancer Research | Evidence of potent #immuneactivation systemically & in #TME supporting an important role for local #IL12 & systemic #antiPD1 regimens in #immunooncology Moffitt Cancer Center aacrjournals.org/clincancerres/…
Congratulations to Neel Jasani who defended his thesis last week and his paper was accepted for publication Cancer Research. Thanks to his committee DeNicola Lab Karen Mann Keiran Smalley Elsa Renee Flores and his external chair @ColoffLab
New paper out! Triplet immune checkpoint immunotherapy can reactivate highly exhausted TIM3+ CD8+ T-cells in melanoma Moffitt Cancer Center Journal for ImmunoTherapy of Cancer jitc.bmj.com/content/13/8/e…
New study from Keiran Smalley published in Journal for ImmunoTherapy of Cancer found that triplet therapy targeting TIM-3 shows potential to overcome checkpoint resistance in preclinical melanoma models
Moffitt Study Finds Promising New Combo Therapy for Drug-Resistant #Melanoma. By blocking TIM-3 in addition to PD-1 and LAG-3, researchers saw a more powerful and targeted immune response, even in difficult-to-treat tumors. Moffitt Cancer Center moffitt.org/newsroom/news-…
So pleased to see this important work published. Congrats in particular to moran amit for this massive effort detailing how cancers cause nerve injury, which in turn leads to an immunosuppressive environment driving immunotherapy resistance. nature.com/articles/s4158…
Treatment-Resistant Melanoma Model Targeted with Triplet Therapy Combining PD-1, LAG-3, and TIM-3 inhibitors overcomes #checkpointresistance in preclinical melanoma models Keiran Smalley Moffitt Cancer Center #melanoma #immunotherapy hubs.li/Q03DHRtb0
New #JITC article: Identification of anti-TIM-3 based checkpoint inhibitor combinations with activity in immunotherapy refractory melanoma models bit.ly/3Jv2QMZ Keiran Smalley Moffitt Cancer Center
Congrats to Keiran Smalley and team on their new Journal for ImmunoTherapy of Cancer paper! A 3-drug #immunotherapy combo may overcome resistance in #melanoma, restoring immune response & shrinking tumors in preclinical models without added side effects. Read more below: bit.ly/47f3atc
Another paper drop! Here we report on the activity of avelumab plus whole brain radiotherapy in patients with leptomeningeal metastases. A great collaboration with Peter Forsyth! Moffitt Cancer Center SNO academic.oup.com/neuro-oncology…
